Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental studies on aclacinomycin.

H Tone, H Nishida, T Takeuchi

    Drugs Under Experimental and Clinical Research
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Two new drainage tubes for minimally invasive cardiac surgery.

    The heart surgery forum·2001
    Same author

    International Child Care Practices Study: infant sleeping environment.

    Early human development·2001
    Same author

    Distribution of genes for lysine biosynthesis through the aminoadipate pathway among prokaryotic genomes.

    Bioinformatics (Oxford, England)·2001
    Same author

    Prognostic value of the colposcopic tumor size in stage IB squamous cervical cancer.

    Journal of surgical oncology·2001
    Same author

    macho-1 encodes a localized mRNA in ascidian eggs that specifies muscle fate during embryogenesis.

    Nature·2001
    Same author

    [A case of myasthenia gravis following sarcoidosis and Hashimoto's thyroiditis].

    Rinsho shinkeigaku = Clinical neurology·2001
    Same journal

    A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.

    Drugs under experimental and clinical research·2006
    Same journal

    Psychiatric factors in patients with sensitive skin.

    Drugs under experimental and clinical research·2006
    Same journal

    Objective biophysical findings in patients with sensitive skin.

    Drugs under experimental and clinical research·2006
    Same journal

    Is itraconazole the treatment of choice in Microsporum canis tinea capitis?

    Drugs under experimental and clinical research·2006
    Same journal

    Improvement of otitis media with effusion after treatment of asthma with leukotriene antagonists in children with co-existing disease.

    Drugs under experimental and clinical research·2006
    Same journal

    Twice-daily dosing of loracarbef 15 mg/kg versus 30 mg/kg in the treatment of children with acute sinusitis.

    Drugs under experimental and clinical research·2006
    See all related articles

    Aclacinomycin (ACM), an anthracycline antibiotic, effectively inhibits tumor growth and shows reduced cardiac toxicity compared to adriamycin (ADR). This new anticancer drug demonstrates significant potential in preclinical cancer models.

    Area of Science:

    • Oncology
    • Pharmacology
    • Biochemistry

    Background:

    • Anthracycline antibiotics are a key class of anticancer drugs.
    • Adriamycin (ADR) is a widely used anthracycline but exhibits significant cardiotoxicity.
    • There is a need for novel anthracyclines with improved therapeutic profiles.

    Purpose of the Study:

    • To evaluate the antitumour activity of a new anthracycline, aclacinomycin (ACM).
    • To compare the efficacy and toxicity of ACM with adriamycin (ADR).
    • To investigate the mechanism of action and safety profile of ACM.

    Main Methods:

    • In vivo studies using experimental mouse tumors and human cancer xenografts.
    • In vitro assessment of RNA and DNA synthesis inhibition in L1210 cells.

    Related Experiment Videos

  • Mutagenicity testing (Ames' test, rec- assay) and cardiac toxicity evaluation in animal models (hamsters, rabbits).

    • Main Results:

    • ACM demonstrated significant inhibition of tumor growth in various models.
    • Combination therapy with ACM and Ara-C resulted in a 459% increase in lifespan (ILS) in CDF1 mice with L1210 cells.
    • ACM exhibited a higher DNA/RNA synthesis inhibition ratio (7.9) compared to ADR (2.5) and showed no mutagenic activity.
    • ACM displayed significantly lower cardiac toxicity than ADR, with faster elimination from heart muscle.

    Conclusions:

    • Aclacinomycin (ACM) is a potent antitumour antibiotic with a favorable efficacy and safety profile.
    • ACM's reduced cardiotoxicity and lack of mutagenicity make it a promising alternative to existing anthracyclines.
    • Further clinical investigation of ACM for cancer treatment is warranted.